Neurocrine Biosciences | Los Gastos De Explotación



Operating Expenses Cambio Fecha
AbbVie USD 9.61B 6.98B 2025-03
Acadia Pharmaceuticals USD 225.03M 118.93M 2025-03
Agios Pharmaceuticals USD 115.35M 20.41M 2025-03
ALKERMES USD 292.72M 25.42M 2025-03
Alnylam Pharmaceuticals USD 576.11M 122.21M 2025-03
Amgen USD 6.86B 85M 2025-03
Biogen USD 2.12B 106.5M 2025-03
BioMarin Pharmaceutical USD 521.25M 64.65M 2025-03
Cytokinetics USD 157.21M 1.24M 2025-03
Dynavax Technologies USD 91.79M 18.13M 2025-03
Exelixis USD 368.59M 34.96M 2025-04
Gilead Sciences USD 4.43B 687M 2025-03
Halozyme Therapeutics USD 123.33M 819K 2025-03
Incyte USD 847.73M 29.46M 2025-03
Ionis Pharmaceuticals USD 278M 59.4M 2025-03
Neurocrine Biosciences USD 485.7M 47.4M 2024-12
Pfizer USD 10.05B 8.12B 2025-03
Prothena USD 67.02M 463K 2024-12
Regeneron Pharmaceuticals USD 2.44B 362M 2025-03
Repligen USD 162.59M 41.45M 2025-03
Sarepta Therapeutics USD 1.05B 548.51M 2025-03
Teva Pharmaceutical Industries USD 3.37B 402M 2025-03
Ultragenyx Pharmaceutical USD 282.23M 4.92M 2025-03
Vertex Pharmaceuticals USD 1.89B 230.4M 2024-12



Neurocrine Biosciences Los Gastos De Explotación - Los valores actuales, los datos históricos, las previsiones, estadísticas, gráficas y calendario económico - May 2025.